Fortress Biotech (FRA:CNB1) Ending Cash Position : €78.97 Mil (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Ending Cash Position?

Fortress Biotech's Ending Cash Position for the quarter that ended in Mar. 2024 was €78.97 Mil.

Fortress Biotech's quarterly Ending Cash Position increased from Sep. 2023 (€70.04 Mil) to Dec. 2023 (€76.45 Mil) and increased from Dec. 2023 (€76.45 Mil) to Mar. 2024 (€78.97 Mil).

Fortress Biotech's annual Ending Cash Position declined from Dec. 2021 (€272.55 Mil) to Dec. 2022 (€170.82 Mil) and declined from Dec. 2022 (€170.82 Mil) to Dec. 2023 (€76.45 Mil).

Fortress Biotech Ending Cash Position Historical Data

The historical data trend for Fortress Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Ending Cash Position Chart

Fortress Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

138.09

193.17

272.55

170.82

76.45

Fortress Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															144.70	82.34	70.04	76.45	78.97

Fortress Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Fortress Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	165.934	+	-89.488
	=	76.45

Fortress Biotech's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	76.696	+	2.274
	=	78.97

Fortress Biotech Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (FRA:CNB1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA FBIO:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines